

Amendments to the Claims

1. **(Original)** An aqueous suspension comprising loteprednol etabonate and at least one member selected from the group consisting of sorbic acid, salts thereof and p-hydroxybenzoic acid esters.

2. **(Original)** The aqueous suspension according to Claim 1 wherein a non-ionic surfactant is additionally contained.

3. **(Currently amended)** The aqueous suspension according to Claim 1 ~~or~~2 wherein the suspension is an eye-drop.

4. **(Currently amended)** The aqueous suspension according to Claim 1 ~~or~~2 wherein the suspension is a nasal-drop.

5. **(Currently amended)** The aqueous suspension according to Claim 1 ~~or~~2 wherein the suspension is an ear-drop.

6. **(Original)** A method for improving redispersibility of loteprednol etabonate which comprises compounding at least one member selected from the group consisting of sorbic acid, salts thereof and p-hydroxybenzoic acid esters in an aqueous suspension containing loteprednol etabonate.

7. **(New)** The aqueous suspension according to Claim 2 wherein the suspension is an eye-drop.

8. **(New)** The aqueous suspension according to Claim 2 wherein the suspension is a nasal-drop.

9. (New) The aqueous suspension according to Claim 2 wherein the suspension is an ear-drop.